RBC Capital raised the firm’s price target on Tenet Healthcare (THC) to $183 from $174 and keeps an Outperform rating on the shares after its Q3 results. The company saw solid recovery from recent weakness across the hospital segment following a solid Q3 beat and guidance raise, the analyst tells investors in a research note. Tenet’s early views on 2025 also suggest continuation of strong volume trends into next year and continued capacity expansion, the firm added.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare Reports Strong Q3 Results and Raises Outlook
- McDonald’s, Ford, Pfizer report Q3 earnings beats: Morning Buzz
- Tenet Healthcare reports Q3 adjusted EPS $2.93 vs. $1.44 last year
- Tenet Healthcare raises FY24 adjusted EPS view to $11.12-$11.73
- Tenet Healthcare sees Q4 adjusted EPS $2.20-$3.24